-
1
-
-
0019424458
-
Hirsutism: Implications, etiology, and management
-
Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981;140:815-30. (Pubitemid 11046650)
-
(1981)
American Journal of Obstetrics and Gynecology
, vol.140
, Issue.7
, pp. 815-830
-
-
Hatch, R.1
Rosenfield, R.L.2
Kim, M.H.3
Tredway, D.4
-
2
-
-
34547564845
-
Dermatologic manifestations of polycystic ovary syndrome
-
DOI 10.2165/00128071-200708040-00003
-
Lee AT, Zane LT. Dermatologic manifestations of polycystic ovary syndrome. Am J Clin Dermatol 2007;8:201-19. (Pubitemid 47195665)
-
(2007)
American Journal of Clinical Dermatology
, vol.8
, Issue.4
, pp. 201-219
-
-
Lee, A.T.1
Zane, L.T.2
-
3
-
-
0347362877
-
Quality of Life, Psychosocial Well-Being, and Sexual Satisfaction in Women with Polycystic Ovary Syndrome
-
DOI 10.1210/jc.2003-030562
-
Elsenbruch S, Hahn S, Kowalsky D, Öffner AH, Schedlowski M, Mann K et al. Quality of life, psychosocial wellbeing, and sexual satisfaction in women with polycistic ovary syndrome. J Clin Endocrinol Metab 2003;88:5801-7. (Pubitemid 38033054)
-
(2003)
Journal of Clinical Endocrinology and Metabolism
, vol.88
, Issue.12
, pp. 5801-5807
-
-
Elsenbruch, S.1
Hahn, S.2
Kowalsky, D.3
Offner, A.H.4
Schedlowski, M.5
Mann, K.6
Janssen, O.E.7
-
4
-
-
29644432627
-
Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome
-
DOI 10.1530/eje.1.02024
-
Hahn S, Janssen OE, Tan S, Pleger K, Mann K, Schedlowski M et al. Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. Eur J Endocrinol 2005;153:853-60. (Pubitemid 43020236)
-
(2005)
European Journal of Endocrinology
, vol.153
, Issue.6
, pp. 853-860
-
-
Hahn, S.1
Janssen, O.E.2
Tan, S.3
Pleger, K.4
Mann, K.5
Schedlowski, M.6
Kimmig, R.7
Benson, S.8
Balamitsa, E.9
Elsenbruch, S.10
-
5
-
-
0346725827
-
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome
-
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group
-
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
-
(2004)
Fertil Steril
, vol.81
, pp. 19-25
-
-
-
7
-
-
0036547728
-
The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea
-
van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002;69:2-15.
-
(2002)
Cutis
, vol.69
, pp. 2-15
-
-
Van Vloten, W.A.1
Van Haselen, C.W.2
Van Zuuren, E.J.3
Gerlinger, C.4
Heithecker, R.5
-
8
-
-
33847027994
-
Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism
-
Batukan C, Muderris H, Ozcelik B, Ozturk B, Ozturk A. Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism. Gynecol Endocrinol 2007;23:38-44.
-
(2007)
Gynecol Endocrinol
, vol.23
, pp. 38-44
-
-
Batukan, C.1
Muderris, H.2
Ozcelik, B.3
Ozturk, B.4
Ozturk, A.5
-
9
-
-
64349093259
-
Effects of two estroprogestins containing ethynilestradiol 30 mg and drospirenone 3 mg and ethynilestradiol 30 mg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations
-
Lello S, Primavera G, Colonna L, Vittori G, Guardianelli F, Sorge R et al. Effects of two estroprogestins containing ethynilestradiol 30 mg and drospirenone 3 mg and ethynilestradiol 30 mg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations. Gynecol Endocrinol 2008;24:718-23.
-
(2008)
Gynecol Endocrinol
, vol.24
, pp. 718-723
-
-
Lello, S.1
Primavera, G.2
Colonna, L.3
Vittori, G.4
Guardianelli, F.5
Sorge, R.6
-
10
-
-
40649128938
-
Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: A randomized, double-blind, placebo-controlled trial
-
Koltun W, Lucky AW, Thiboutot D, Niknian M, Sampson-Landers C, Korner P et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception 2008;77:249-56.
-
(2008)
Contraception
, vol.77
, pp. 249-256
-
-
Koltun, W.1
Lucky, A.W.2
Thiboutot, D.3
Niknian, M.4
Sampson-Landers, C.5
Korner, P.6
-
11
-
-
55449126686
-
Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen. A randomized controlled trial
-
Maloney JM, Dietze P Jr, Watson D, Niknian M, Lee-Rugh S, Sampson-Landers C et al. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen. A randomized controlled trial. Obstet Gynecol 2008;112:773-81.
-
(2008)
Obstet Gynecol
, vol.112
, pp. 773-781
-
-
Maloney, J.M.1
Dietze Jr., P.2
Watson, D.3
Niknian, M.4
Lee-Rugh, S.5
Sampson-Landers, C.6
-
13
-
-
0031154916
-
A comparison of current acne grading systems and proposal of a novel system
-
Doshi A, Zaheer A, Stiller MJ. A comparison of current acne grading systems and proposal of a novel system. Int J Dermatol 1997;36:416-8.
-
(1997)
Int J Dermatol
, vol.36
, pp. 416-418
-
-
Doshi, A.1
Zaheer, A.2
Stiller, M.J.3
-
14
-
-
0029051752
-
Drospirenone: A novel progestogen with antimineralocorticoid and antiandrogenic activity
-
Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann NY Acad Sci 1995;761:311-35.
-
(1995)
Ann NY Acad Sci
, vol.761
, pp. 311-335
-
-
Muhn, P.1
Fuhrmann, U.2
Fritzemeier, K.H.3
Krattenmacher, R.4
Schillinger, E.5
-
15
-
-
27744554128
-
Drospirenone in combination with estrogens: For contraception and hormone replacement therapy
-
DOI 10.1080/13697130500330341
-
Oelkers WH. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. Climacteric 2005;3:19-27. (Pubitemid 41608060)
-
(2005)
Climacteric
, vol.8
, Issue.SUPPL. 3
, pp. 19-27
-
-
Oelkers, W.H.K.1
-
16
-
-
69049090802
-
Skin barrier disruption by acetone: Observation in a hairless mouse skin model
-
Rissman R, Oudshoorn MHM, Hennik WE, Ponec M, Bouwstra JA. Skin barrier disruption by acetone: observation in a hairless mouse skin model. Arch Dermatol Res 2009;301:609-13.
-
(2009)
Arch Dermatol Res
, vol.301
, pp. 609-613
-
-
Rissman, R.1
Oudshoorn, M.H.M.2
Hennik, W.E.3
Ponec, M.4
Bouwstra, J.A.5
-
18
-
-
0015187928
-
The effect of oestrogenic treatment on the acid mucopolysaccaride pattern in skin of mice
-
Grosman N, Hvidberg E, Schou J. The effect of oestrogenic treatment on the acid mucopolysaccaride pattern in skin of mice. Acta Pharmacol Toxicol 1971;30:458-64.
-
(1971)
Acta Pharmacol Toxicol
, vol.30
, pp. 458-464
-
-
Grosman, N.1
Hvidberg, E.2
Schou, J.3
-
19
-
-
0018837325
-
The mechanism of estrogen-induced increase in hyaluronic acid biosynthesis, with special reference to estrogen receptor in the mouse skin
-
Uzuka M, Nakajima K, Ohta S, Mori Y. The mechanism of estrogen-induced increase in hyaluronic acid biosynthesis, with special reference to estrogen receptor in the mouse skin. Biochim Biophys Acta 1980;627:199-206.
-
(1980)
Biochim Biophys Acta
, vol.627
, pp. 199-206
-
-
Uzuka, M.1
Nakajima, K.2
Ohta, S.3
Mori, Y.4
-
20
-
-
0029156254
-
Skin water-holding capacity and transdermal estrogen therapy for menopause: A pilot study
-
Pierard-Franchimond C, Letane C, Goffin V, Pierard GE. Skin water-holding capacity and transdermal estrogen therapy for menopause: a pilot study. Maturitas 1995;22: 151-4.
-
(1995)
Maturitas
, vol.22
, pp. 151-154
-
-
Pierard-Franchimond, C.1
Letane, C.2
Goffin, V.3
Pierard, G.E.4
|